FY2024 EPS Estimates for Journey Medical Raised by Analyst

Journey Medical Co. (NASDAQ:DERM) – Equities researchers at Roth Capital boosted their FY2024 earnings per share (EPS) estimates for Journey Medical in a research note issued on Monday, November 4th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of ($0.93) per share for the year, up from their prior estimate of ($0.96). The consensus estimate for Journey Medical’s current full-year earnings is ($1.04) per share. Roth Capital also issued estimates for Journey Medical’s Q4 2024 earnings at ($0.12) EPS.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The company had revenue of $14.86 million during the quarter, compared to the consensus estimate of $13.81 million. Journey Medical had a net margin of 1.09% and a return on equity of 5.44%. During the same period last year, the company earned ($0.46) earnings per share.

Other analysts also recently issued reports about the company. Rodman & Renshaw initiated coverage on Journey Medical in a research note on Thursday, August 22nd. They issued a “buy” rating and a $9.00 price target for the company. Lake Street Capital assumed coverage on shares of Journey Medical in a report on Friday, September 6th. They issued a “buy” rating and a $9.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $9.38.

Journey Medical Stock Up 5.0 %

Journey Medical stock opened at $5.71 on Thursday. The company has a debt-to-equity ratio of 1.75, a current ratio of 1.36 and a quick ratio of 1.08. The company’s 50-day moving average is $5.55 and its 200-day moving average is $4.97. The firm has a market capitalization of $118.37 million, a PE ratio of -285.50 and a beta of 0.92. Journey Medical has a fifty-two week low of $2.85 and a fifty-two week high of $8.11.

Hedge Funds Weigh In On Journey Medical

A number of large investors have recently made changes to their positions in DERM. Nwam LLC purchased a new position in shares of Journey Medical in the 1st quarter worth about $41,000. TMD Wealth Management LLC bought a new stake in shares of Journey Medical in the 2nd quarter worth approximately $65,000. ORG Wealth Partners LLC purchased a new stake in shares of Journey Medical in the third quarter worth $110,000. Heron Bay Capital Management bought a new stake in Journey Medical during the 1st quarter valued at about $124,000. Finally, Rosalind Advisors Inc. purchased a new position in Journey Medical in the 2nd quarter worth approximately $644,000. 7.25% of the stock is owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.